Approved indications: Aristada (aripiprazole lauroxil) is FDA-approved only for the treatment of schizophrenia in adults; it is not approved for children or for other conditions such as bipolar disorder, depression, or dementia-related psychosis.

Off-label uses: Some clinicians may occasionally use Aristada off label in adults with conditions where oral aripiprazole is effective (for example, schizoaffective disorder or bipolar I disorder maintenance), but direct clinical trial evidence for these specific uses with Aristada is limited and decisions are typically based on extrapolation from oral aripiprazole and from other aripiprazole long-acting injectables.

Efficacy expectations and time course: In acute schizophrenia, symptom improvement with Aristada plus short-term oral aripiprazole has been seen as early as about one week, with larger and clinically meaningful improvements over 4–12 weeks; for maintenance treatment, Aristada reduces relapse risk and helps keep symptoms stable when injections are continued on schedule.

Typical outcomes: Many patients experience reductions in hallucinations, paranoia, disorganized thinking, and agitation, along with better functioning and fewer hospitalizations, although individual response varies and some people need dose adjustments or a different medication.

Comparison with similar drugs: Compared with some other long-acting atypical antipsychotics, Aristada tends to have a relatively low risk of weight gain, cholesterol and blood sugar changes, and prolactin elevation, but a notable risk of akathisia (inner restlessness); overall antipsychotic effectiveness is comparable to other modern long-acting injectables when appropriately dosed.

Typical dosing and how it is given: Aristada is given only as an intramuscular injection by a healthcare professional, usually in the buttock (gluteal muscle) and, for the 441 mg dose, sometimes in the shoulder (deltoid). Common maintenance regimens are 441 mg, 662 mg, or 882 mg every month, 882 mg every 6 weeks, or 1064 mg every 2 months; the choice is based on the person’s prior oral aripiprazole dose, symptom control, tolerability, and convenience.

Starting treatment: Before the first injection, people who have never taken aripiprazole are usually given oral aripiprazole briefly to be sure they tolerate it. To reach effective blood levels quickly, clinicians either give a one-time Aristada Initio injection plus a single 30 mg oral aripiprazole dose together with the first Aristada injection, or they continue oral aripiprazole for 21 days after the first Aristada dose.

Administration details for patients: Aristada should not be self-injected; it is prepared and injected in the clinic or another healthcare setting, typically on a regular schedule (for example, every 4 weeks) that should be kept as closely as possible.

Special dosing instructions: Dose or interval adjustments may be needed if side effects occur, if strong CYP2D6 or CYP3A4 inhibitor or inducer medications are added for more than about 2 weeks, or if the person is a known CYP2D6 poor metabolizer; these changes are planned and supervised by the prescriber.

Missed-dose guidance: If you miss or are late for an injection appointment, contact your healthcare provider as soon as possible; they will schedule the next injection promptly and, depending on how much time has passed and your Aristada dose, may add a brief course of oral aripiprazole or a one-time Aristada Initio injection to keep drug levels steady. Do not try to "make up" a dose yourself.

Overdose: Because Aristada is administered only by healthcare professionals, overdose is uncommon, but receiving more than the intended dose or an injection too early could increase side effects such as severe restlessness, drowsiness, abnormal movements, very low blood pressure, or heart rhythm changes; such situations should be treated as medical urgencies and evaluated immediately by medical staff.

Common side effects: The most frequent side effect is akathisia (feeling very restless or unable to sit still); others include injection-site pain, headache, insomnia, anxiety, nausea, mild weight gain, and fatigue. These effects often appear in the first days to weeks after starting or changing dose and may lessen over time or with dose adjustment or added treatments.

• Metabolic effects such as weight gain, increases in blood sugar, or changes in cholesterol can occur but on average are smaller with Aristada than with many other atypical antipsychotics.
• Prolactin levels often stay normal or decrease, so prolactin-related problems (breast tenderness, menstrual changes, sexual dysfunction) are less common than with some other agents.

Serious or rare adverse effects needing urgent care: Contact emergency services or seek immediate medical care for signs of neuroleptic malignant syndrome (high fever, severe muscle stiffness, confusion, fast heart rate, sweating), severe allergic reaction (rash, swelling of face or throat, trouble breathing), significant uncontrollable movements (possible tardive dyskinesia), seizures, very rigid or painful muscles with dark urine, or sudden weakness, trouble speaking, or vision changes that could signal stroke.

Impulse-control problems: Aripiprazole has been linked to new or increased urges such as compulsive gambling, spending, binge eating, or unusual sexual behaviors; report any new strong or out-of-character urges promptly, as dose changes or medication changes often resolve them.

Warnings and precautions: Aristada carries the class boxed warning that antipsychotics increase the risk of death in older adults with dementia-related psychosis and is not approved for this use. Use cautiously in people with a history of diabetes, high cholesterol, obesity, heart disease, low blood pressure, seizures, or low white blood cell counts, and in those who are dehydrated or at risk for overheating.

Pregnancy and breastfeeding: Use during the third trimester can cause withdrawal or movement symptoms in newborns; prescribing in pregnancy weighs maternal benefit against potential fetal risks. Aripiprazole passes into breast milk and may reduce milk supply, so the decision to breastfeed while on Aristada should balance the benefits of breastfeeding, the mother’s need for treatment, and potential effects on the infant, with close monitoring of the baby’s weight and hydration.

Age limits: Safety and effectiveness are not established in people under 18 years; in older adults without dementia, doses may need to be lower and side effects (such as low blood pressure, falls, and stroke) monitored more carefully.

Relative safety compared with other antipsychotics: Overall, Aristada tends to have a favorable metabolic and prolactin profile relative to many other second-generation antipsychotics but may cause more akathisia and activation in some patients; like all antipsychotics it still carries risks of movement disorders, neuroleptic malignant syndrome, and metabolic changes.

Side-effect reporting and safety updates: Patients and caregivers can report suspected side effects to their healthcare provider, to the manufacturer’s drug safety line, or directly to the FDA’s MedWatch program, and should periodically review the Medication Guide that is dispensed with each injection for updated safety information.

Prescription and OTC drug interactions: Medications that strongly affect liver enzymes CYP3A4 or CYP2D6 (such as certain antifungals, antibiotics, HIV drugs, some antidepressants, or seizure medicines) can increase or decrease aripiprazole levels and may require Aristada dose changes or, in some combinations, should be avoided. Other antipsychotics, benzodiazepines, opioids, sedating antihistamines, and sleep medicines can add to drowsiness, dizziness, or impaired coordination.

• Drugs that lower blood pressure (for example, some blood pressure pills, alpha-blockers) may increase the risk of lightheadedness or fainting when combined with Aristada.
• Use caution with medications that can prolong the QT interval or significantly disturb electrolytes, especially in people with underlying heart disease, even though aripiprazole itself has relatively low QT-prolongation risk.

Supplements, foods, and alcohol: Herbal products or supplements that affect CYP3A4 (such as St. John’s wort) can alter drug levels. Alcohol can enhance dizziness, drowsiness, and judgment impairment, so many clinicians recommend avoiding or strictly limiting alcohol while on Aristada.

Medical conditions requiring extra caution: Extra care is needed in people with a history of diabetes or prediabetes, high cholesterol, obesity, cardiovascular or cerebrovascular disease, low blood pressure, seizures, liver impairment, or prior low white blood cell counts, and in those prone to heat exhaustion or dehydration.

Monitoring needs: Routine monitoring usually includes weight and body mass index, waist circumference, blood pressure and pulse, and periodic fasting blood glucose or A1c and lipid panel; many clinicians also perform movement exams to check for abnormal involuntary movements and ask specifically about restlessness and impulse-control symptoms.

When to alert your prescriber: Tell your clinician about all prescription drugs, over-the-counter medicines, and supplements you take before starting Aristada, and notify them promptly if any new medication is added, if you become pregnant or plan pregnancy, if you develop severe restlessness, new compulsive behaviors, or signs of high blood sugar, or if you have fainting, chest pain, stroke-like symptoms, or severe infection.

Q: What is Aristada and how is it different from oral aripiprazole (Abilify)?
A: Aristada is a long-acting intramuscular injection that slowly releases aripiprazole over weeks, so it is given every 4 to 8 weeks instead of taking a pill every day; the active medicine is the same as in Abilify, but the formulation and dosing schedule are different.

Q: How long does it take for Aristada to start working?
A: When started with oral aripiprazole or Aristada Initio as directed, some people notice symptom improvement within 1 to 2 weeks, with fuller benefits typically developing over about 4 to 12 weeks of consistent treatment.

Q: What happens if I miss an Aristada injection appointment?
A: Call your clinic as soon as possible so they can give the next injection promptly; depending on how late it is, they may also prescribe short-term oral aripiprazole or a one-time Aristada Initio dose to keep drug levels steady.

Q: Will Aristada make me gain weight?
A: Aristada can cause some weight gain, but on average the amount is modest and generally less than with several other atypical antipsychotics; your provider will usually monitor your weight and may suggest lifestyle changes if weight starts to increase.

Q: Can I drink alcohol while receiving Aristada?
A: Drinking alcohol while on Aristada can increase drowsiness, dizziness, and judgment impairment, so most clinicians recommend avoiding or minimizing alcohol and never drinking to the point of intoxication.

Q: Is Aristada safe during pregnancy or breastfeeding?
A: Use in pregnancy or while breastfeeding requires a careful risk–benefit discussion; Aristada may be continued when the benefits clearly outweigh risks, but newborns can have withdrawal or movement symptoms and the drug passes into breast milk, so close monitoring of mother and baby is important.

Q: How long will I need to stay on Aristada?
A: Schizophrenia is usually a long-term condition, and if Aristada is effective and well tolerated, many people stay on it for years to help prevent relapse, with the decision to continue or adjust treatment revisited regularly with their mental health provider.

Storage: Aristada comes as a prefilled syringe meant to be stored and administered by healthcare professionals, usually at room temperature (about 68–77°F / 20–25°C) in its original carton, kept flat to prevent clogging, and kept out of the reach of children.

Patient handling: Most patients will not store Aristada at home or inject it themselves; if you are ever given a syringe to bring to the clinic, carry it in the original packaging at room temperature, do not freeze it, do not shake it excessively, and keep it away from heat, moisture, and sunlight.

Disposal: Used or expired Aristada syringes should be disposed of in a sharps container or returned to a clinic or pharmacy; do not throw syringes or needles into household trash and do not flush them down the toilet.